Literature DB >> 19582519

An analysis of trends and growth factor receptor expression of GI carcinoid tumors.

Kanika A Bowen1, Scott R Silva, Jessica N Johnson, Hung Q Doan, Lindsey N Jackson, Pat Gulhati, Suimin Qiu, Taylor S Riall, B Mark Evers.   

Abstract

INTRODUCTION: The purpose of our study was twofold: (1) to determine the incidence, patient and tumor characteristics, and outcome of patients with gastrointestinal carcinoid tumors using the Surveillance, Epidemiology and End Results (SEER) database, and (2) to delineate the expression pattern of growth factor receptors (GFRs) in carcinoid tumors.
MATERIALS AND METHODS: The SEER database search provided information on patients diagnosed with carcinoid tumors from 1990 to 2002. Carcinoid tumor sections (n = 46) were stained for the GFRs: epidermal growth factor receptor, insulin-like growth factor receptor (IGFR), vascular endothelial growth factor receptor (VEGFR), and HER-2/neu.
RESULTS: Over the 12-year analysis period, 18,180 patients were identified with carcinoid tumors of the foregut, midgut, and hindgut; the incidence of carcinoid tumors increased approximately 2-fold during this time period. Of the patients with carcinoid tumors, there was a trend of increased expression of VEGFR and IGFR, particularly in the foregut and midgut carcinoids. Analysis of the SEER database confirms that the incidence of carcinoid tumors is increasing with an approximate doubling in the number of carcinoid cases from 1990 to 2002. Furthermore, an increase in VEGFR and IGFR expression suggests that GFR inhibitors may be effective adjuvant therapy for carcinoid cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582519      PMCID: PMC2902268          DOI: 10.1007/s11605-009-0958-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  35 in total

1.  The human carcinoid cell line, BON. A model system for the study of carcinoid tumors.

Authors:  B M Evers; J Ishizuka; C M Townsend; J C Thompson
Journal:  Ann N Y Acad Sci       Date:  1994-09-15       Impact factor: 5.691

Review 2.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

3.  Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth.

Authors:  B M Evers; C M Townsend; J R Upp; E Allen; S C Hurlbut; S W Kim; S Rajaraman; P Singh; J C Reubi; J C Thompson
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682

4.  Expression of vascular endothelial growth factor in digestive neuroendocrine tumours.

Authors:  B Terris; J Y Scoazec; L Rubbia; L Bregeaud; M S Pepper; P Ruszniewski; J Belghiti; J Fléjou; C Degott
Journal:  Histopathology       Date:  1998-02       Impact factor: 5.087

5.  Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas.

Authors:  Mathias Gugger; Elisabeth Burckhardt; Andreas Kappeler; Hans Hirsiger; Jean A Laissue; Luca Mazzucchelli
Journal:  J Pathol       Date:  2002-04       Impact factor: 7.996

6.  Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells.

Authors:  G von Wichert; P M Jehle; A Hoeflich; S Koschnick; H Dralle; E Wolf; B Wiedenmann; B O Boehm; G Adler; T Seufferlein
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

7.  Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1).

Authors:  Veronica Galvan; Anna Logvinova; Sabina Sperandio; Hidenori Ichijo; Dale E Bredesen
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

8.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

9.  Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?

Authors:  O Nilsson; B Wängberg; E Theodorsson; A Skottner; H Ahlman
Journal:  Int J Cancer       Date:  1992-05-08       Impact factor: 7.396

10.  Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53.

Authors:  S Ambs; W P Bennett; W G Merriam; M O Ogunfusika; S M Oser; M A Khan; R T Jones; C C Harris
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more
  9 in total

1.  VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Authors:  Scott R Silva; Kanika A Bowen; Piotr G Rychahou; Lindsey N Jackson; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

Review 2.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

3.  The effect of PTEN on serotonin synthesis and secretion from the carcinoid cell line BON.

Authors:  Scott R Silva; Yekaterina Y Zaytseva; Lindsey N Jackson; Eun Y Lee; Heidi L Weiss; Kanika A Bowen; Courtney M Townsend; B Mark Evers
Journal:  Anticancer Res       Date:  2011-04       Impact factor: 2.480

Review 4.  New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.

Authors:  Ben Lawrence; Bjorn I Gustafsson; Mark Kidd; Irvin Modlin
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

5.  Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

Authors:  Jennifer A Chan; Robert J Mayer; Nadine Jackson; Paige Malinowski; Eileen Regan; Matthew H Kulke
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-09       Impact factor: 3.333

6.  Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.

Authors:  Ji Tae Kim; Jing Li; Eun Ryoung Jang; Pat Gulhati; Piotr G Rychahou; Dana L Napier; Chi Wang; Heidi L Weiss; Eun Y Lee; Lowell Anthony; Courtney M Townsend; Chunming Liu; B Mark Evers
Journal:  Carcinogenesis       Date:  2013-01-25       Impact factor: 4.944

Review 7.  Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms.

Authors:  Namrata Vijayvergia; Arvind Dasari
Journal:  Curr Treat Options Oncol       Date:  2020-10-07

Review 8.  Targeting the mTOR signaling pathway in neuroendocrine tumors.

Authors:  Jennifer Chan; Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2014-09

9.  Can insulin-like growth factor 1 (IGF-1), IGF-1 receptor connective tissue growth factor and Ki-67 labelling index have a prognostic role in pulmonary carcinoids?

Authors:  Georgios A Kanakis; Lars Grimelius; Dimitrios Papaioannou; Gregory Kaltsas; Apostolos V Tsolakis
Journal:  Oncotarget       Date:  2018-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.